Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Satellite Biosciences Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are distributed among 3 distinct examiners and 3 distinct art units. TRAN, KHOA NHAT is the busiest examiner for the company, currently overseeing 1 pending office action. The 3 pending office actions are spread evenly across 3 distinct examiners, meaning no single individual handles more than one case.
Furthermore, the 3 distinct art units involved indicate that each application is being reviewed by a different department. This distribution requires the company to manage three separate prosecution environments simultaneously. Practitioners must tailor every response to the specific expectations of the 3 distinct examiners and the 3 distinct art units currently reviewing the applications. There is no examiner overlap to leverage for consistency, making each of the 3 pending office actions an independent negotiation within the Biotechnology & Pharmaceuticals technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, KHOA NHAT | 1 | 41.9% | +50.5% |
| PELLEGRINO, BRIAN E | 1 | 55.4% | +35.9% |
| GU, QINHUA | 1 | 76.2% | +27.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19060439 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION OF HEPATOCYTES | TRAN, KHOA NHAT | — |
| 18646092 | ENGINEERED TISSUE CONSTRUCTS AND USES THEREOF | PELLEGRINO, BRIAN E | — |
| 18704122 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION AND/OR MATURATION OF HEPATOCYTES | GU, QINHUA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19060439 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION OF HEPATOCYTES | TRAN, KHOA NHAT | — |
| 18646092 | ENGINEERED TISSUE CONSTRUCTS AND USES THEREOF | PELLEGRINO, BRIAN E | — |
| 18704122 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION AND/OR MATURATION OF HEPATOCYTES | GU, QINHUA | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 3799 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19060439 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION OF HEPATOCYTES | TRAN, KHOA NHAT | 1632 | §102§103 | Final Rejection | — | Pending | Feb 21, 2025 |
| 18646092 | ENGINEERED TISSUE CONSTRUCTS AND USES THEREOF | PELLEGRINO, BRIAN E | 3799 | §102§103§112Other | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18704122 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION AND/OR MATURATION OF HEPATOCYTES | GU, QINHUA | 1633 | §102§103§112Other | Non-Final OA | — | Pending | Apr 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSatellite Biosciences Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Khoa Nhat Tran has the most, with 1 of Satellite Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
